Generalized Pruritus Management

Initial Evaluation and Laboratory Investigations

The British Journal of Dermatology recommends that all patients with generalized pruritus without an obvious dermatologic cause should receive a focused laboratory workup including complete blood count with ferritin, liver function tests, urea and electrolytes, and consideration of HIV/hepatitis serology based on risk factors 1, 2, 3
Complete blood count and ferritin levels should be checked in all patients with chronic generalized pruritus without rash to screen for iron deficiency, polycythemia vera, and hematologic malignancies 2, 3
Liver function tests are essential to evaluate for hepatic causes, with consideration of bile acids and antimitochondrial antibodies if liver disease is suspected 1, 2, 3
Urea and electrolytes must be obtained to assess for uremic pruritus from renal disease 1, 2, 3

A comprehensive medication review is mandatory, as drug-induced pruritus is a common and reversible cause, according to the British Journal of Dermatology 1, 4
Trial cessation of potentially causative medications should be undertaken when the risk-benefit analysis is acceptable to both clinician and patient 1, 5

The British Journal of Dermatology suggests beginning with self-care advice, emollients, and a short trial of non-sedating antihistamines rather than extensive investigations in primary care 6, 4, 5
Emollients should be prescribed to maintain skin hydration as initial therapy 6, 4, 5
Non-sedating antihistamines can be used as second-line therapy 4, 5
Topical doxepin or topical clobetasone butyrate/menthol preparations can be considered as first-line topical therapies 4, 5

In elderly patients, initiate a 2-week trial of emollients and topical steroids to exclude asteatotic eczema before pursuing extensive workup, as recommended by the British Journal of Dermatology 6, 4, 5
Moisturizers with high lipid content are preferred in elderly patients 6, 5
Sedating antihistamines should be avoided in elderly patients except in palliative care settings due to potential dementia risk 4, 5
Gabapentin may benefit elderly patients with pruritus who have not responded to initial treatment 6

Refer to secondary care when there is diagnostic doubt, symptoms persist despite primary care management, or when specific underlying conditions require specialist input, according to the British Journal of Dermatology 6
Hematology referral is indicated for suspected polycythemia vera or lymphoma 2, 3
Hepatology referral should occur with any suggestion of significant hepatic impairment 1, 2, 3

Do not order routine thyroid function tests without clinical features suggesting endocrinopathy, as recommended by the British Journal of Dermatology 1, 2, 3
Do not pursue extensive malignancy screening in the absence of specific systemic symptoms 1, 2, 3
Do not use long-term sedative antihistamines except in palliative care due to dementia risk 4, 5
Do not overlook medication review as a reversible cause 1, 4
Regular follow-up is essential when the underlying cause is not immediately evident, as systemic causes may not be apparent initially 6

A thorough travel and exposure history is essential to uncover infectious contributors such as HIV, hepatitis viruses, malaria, strongyloidiasis, and schistosomiasis. 7

Liver function tests should be performed in all patients to detect hepatic causes of pruritus; when liver disease is suspected, add bile‑acid measurement and antimitochondrial antibody testing. 7
Serum urea and electrolytes are required to evaluate for uremic pruritus secondary to renal impairment. 7

HIV and hepatitis A, B, and C serologies are indicated when risk factors or clinical context suggest viral infection. 7

Thyroid function testing is not recommended unless additional signs point toward endocrine, diabetic, or renal disorders. 7
Extensive malignancy screening is not routinely advised in the absence of specific systemic symptoms; a full cancer work‑up should be reserved for targeted indications. 7

When drug‑induced pruritus is suspected, a structured trial of discontinuing the potentially offending medication should be undertaken, provided the risk‑benefit assessment is acceptable to both clinician and patient. 7

Patients with laboratory evidence of significant hepatic dysfunction (e.g., abnormal liver function tests) should be referred to a hepatology specialist for further evaluation. 7